Progress of WestVac Biopharma's COVID-19 Vaccine Has Attracted International Attention and Reported by Many Overseas Authoritative Media

Recently, the progress of the second generation COVID-19 vaccine of WestVac BioPharma Co., Ltd. (hereinafter referred to as "WestVac Biopharma") has attracted international media attention, and has been reported by The Associated Press, Asahi Shinbun, Fox News, Agencia EFE and other overseas authoritative media, causing widespread concern in the global society. In just a few days, more than 600 reports were published.

Screenshot of The Associated Press Report(click to view details)

Screenshot of Asahi Shinbun Report(click to view details)

Screenshot of Agencia EFE Report (click to view details)

What kind of information can attract so much international media attention? According to relevant experts, WestVac Biopharma found that WestVac Biopharma’s second generation COVID-19 vaccine against Omicron variant strains can reach ten thousands level of neutralizing antibodies in experiments (it means that it still has the ability to block the virus from infecting cells after the blood is diluted 10,000 times). This vaccine has also been found to have ten thousands of neutralizing antibodies that completely inhibit the euviruses of various variants, including the Brazilian strain, South African strain and Delta strain. This suggests that the vaccine is a universal COVID-19 vaccine against a variety of variant strains, and is also one of the first COVID-19 vaccines with high titers neutralizing antibodies against Omicron variant strains announced in the world [1].

Since the Omicron strain was first reported to the World Health Organization (WHO) by South Africa on November 24, 2021, as of January 2, 2022, 131 countries or regions have reported confirmed cases of the Omicron variant strain, and the cumulative number of confirmed cases of Omicron variant strains globally exceeds 400,000 [2], Omicron has gradually become the dominant variant all over the world. The significant progress made by WestVac Biopharma's second generation COVID-19 vaccines against Omicron under this severe international backdrop is undoubtedly exciting news!


1. Data source: WestVac data on file

2. Data source: Our World in Data